贝伐珠单抗联合顺铂化疗对晚期肺癌患者肿瘤标志物及T淋巴细胞亚群的影响  

Effects of Bevacizumab Combined with Cisplatin Chemotherapy on Tumor Markers and T Lymphocyte Subsets in Patients with Advanced Lung Cancer

作　　者：牛德红[1] 孙玉梅[1] 于法常[1] Niu Dehong;Sun Yumei;Yu Fachang(Department of Oncology and Hematology,Jinan No.5 People's Hospital,Jinan 250022)

机构地区：[1]济南市第五人民医院肿瘤血液科,济南250022

出　　处：《数理医药学杂志》2022年第7期1045-1047,共3页Journal of Mathematical Medicine

摘　　要：目的:研究贝伐珠单抗联合顺铂化疗对晚期肺癌患者肿瘤标志物及T淋巴细胞亚群的影响。方法:选择2018年6月-2021年12月于某院接受诊治的92例晚期肺癌患者作为临床观察对象,按随机数字表法分为对照组和观察组各46例,对照组采用顺铂^(+)培美曲塞或多西他赛联合化疗,观察组在对照组化疗基础上采用贝伐珠单抗,3周作为1个治疗周期,持续用药治疗3个周期。对比两组近期疗效及肿瘤标志物水平[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)及糖类抗原125(CA125)]、T淋巴细胞亚群[CD3^(+)、CD4^(+)、CD8^(+)]、不良反应发生率。结果:观察组的疾病总缓解率(58.70%)较对照组(36.96%)更高,有统计学差异(P<0.05);相比于治疗前,治疗后两组患者血清CYFRA21-1、CEA、CA125水平均降低,且观察组较对照组更低,有统计学差异(P<0.05);与治疗前相比,两组患者治疗后T淋巴细胞亚群指标CD3^(+)、CD4^(+)、CD8^(+)均降低,但观察组高于对照组,有统计学差异(P<0.05);观察组不良反应总发生率(13.04%)较对照组(30.43%)更低,有统计学差异(P<0.05)。结论:贝伐珠单抗与顺铂联合治疗晚期肺癌近期疗效确切,能进一步降低肿瘤标志物表达水平,减轻化疗对免疫功能造成的影响,且用药安全性较高,可于临床推广。Objective:To study the effect of bevacizumab combined with cisplatin chemotherapy on tumor markers and T lymphocyte subsets in patients with advanced lung cancer.Methods:A total of 92 patients with advanced lung cancer who were diagnosed and treated in a hospital from June 2018 to December 2021 were selected as clinical observation objects,and divided into two groups according to the random number table method,with 46 cases in each group.The control group was treated with combined chemotherapy with cisplatin^(+)pemetrexed or docetaxel combined,and the observation group was treated with bevacizumab on the basis of chemotherapy in the control group.3 weeks as a treatment cycle,the treatment was continued for 3 cycles.The short-term efficacy and tumor marker levels[cytokeratin 19 fragment antigen21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],T lymphocyte subsets[CD3^(+),CD4^(+),CD8^(+)],and the incidence of adverse reactions were compared between the two groups.Results:The total remission rate of the disease in the observation group(58.70%)was higher than that in the control group(36.96%),with statistical difference(P<0.05).Compared with before treatment,the serum levels of CYFRA21-1,CEA,and CA125 were decreased after treatment,and the observation group was lower than the control group,with statistical difference(P<0.05).Compared with before treatment,the T lymphocyte subset indexes CD3^(+),CD4^(+),and CD8^(+)in the two groups were decreased,and the observation group was higher than the control group,with statistical difference(P<0.05).The total incidence of adverse reactions in the observation group(13.04%)was lower than that in the control group(30.43%),with statistical difference(P<0.05).Conclusion:The combination of bevacizumab and cisplatin is effective in the treatment of advanced lung cancer in the short term,which can further reduce the expression level of tumor markers and reduce the impact of chemotherapy on immune function,with high safety,and can be promoted in clinical pr

关 键 词：贝伐珠单抗 顺铂 晚期肺癌 肿瘤标志物 T淋巴细胞亚群 

分 类 号：R734.2[医药卫生—肿瘤]